DiscGenics’ IDCT Passes Initial Safety Review in Phase I/II Trial

DiscGenics' injectable disc cell therapy (IDCT) passed the initial planned safety review of its Phase I/II trial for the treatment of mild to moderate degenerative disc disease.

An independent data safety monitoring committee recommended no changes to the trial protocol after review of the first six subjects, who were randomly assigned to...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us